Neurocrine Biosciences Presents Data At MDS International Congress of Parkinson's Disease and Movement Disorders Demonstrating Comparable Improvement Over Time In Tardive Dyskinesia Severity And Impact Following Treatment With INGREZZA Capsules
Portfolio Pulse from Happy Mohamed
Neurocrine Biosciences (NBIX) presented data from a study of its INGREZZA capsules at the MDS International Congress of Parkinson's Disease and Movement Disorders. The data showed comparable improvement over time in tardive dyskinesia (TD) severity and impact following treatment with INGREZZA. The study evaluated the use of INGREZZA for the treatment of TD among 167 patients with either schizophrenia or mood disorders. The results suggested that TD severity and patient-reported assessment of the physical, social, and emotional impact of TD decreased with INGREZZA treatment over the course of the 48-week study.
August 29, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences presented positive data on its INGREZZA capsules for the treatment of tardive dyskinesia, which could potentially boost the company's reputation and sales.
The positive data presented by Neurocrine Biosciences on its INGREZZA capsules for the treatment of tardive dyskinesia could potentially increase the demand for the product, leading to increased sales and a positive impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100